The next generation of metabolic peptides may be about much more than weight loss.

Educational content only. Nothing in this article constitutes medical advice or a recommendation to use an investigational or unapproved drug.

For the past few years, the conversation around GLP-1 drugs has largely centered on one thing: weight loss. Retatrutide may change that conversation.

New Phase 3 research on Eli Lilly’s investigational retatrutide is producing some of the most striking results ever seen in metabolic medicine. The findings reach beyond a number on the scale to obesity-related conditions involving blood sugar, joints, sleep, cardiovascular risk, and metabolic health.

For readers looking for foundational knowledge of this peptide category, explore Peptides Costa Rica’s weight-management research and its Retatrutide research overview.

What Makes Retatrutide Different?

Retatrutide, also known as LY3437943, is a triple hormone-receptor agonist. Rather than targeting only GLP-1, it activates three receptors:

GLP-1 + GIP + glucagon

That third component, glucagon, is particularly interesting. The strategy is designed to influence appetite and glucose regulation and also  to affect energy expenditure and metabolism.

The original peer-reviewed Phase 2 study published in the New England Journal of Medicine gave researchers an early indication of its potential. At 48 weeks, participants receiving the highest studied dose experienced an average 24.2% reduction in body weight, compared with 2.1% with placebo. In that group, 26% of participants lost 30% or more of their body weight. Read the Phase 2 study in NEJM.

Nearly 30% Average Weight Loss in Phase 3

In the Phase 3 TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average 28.3% of their body weight over 80 weeks; approximately 70 pounds on average. More than 65% of participants receiving the highest dose reached a BMI below 30, meaning they no longer met the BMI definition of obesity. See Lilly’s TRIUMPH-1 results announcement.

Those results help explain why retatrutide has drawn so much attention. But weight loss may be only part of the story.

Joint Pain: A Surprising Signal

TRIUMPH-4 studied people with obesity or overweight who also had knee osteoarthritis. Participants receiving retatrutide 12 mg lost an average 28.7% of their body weight over 68 weeks. At the same time, knee osteoarthritis pain scores fell by approximately 74% to 76% in the retatrutide groups.

In a post-hoc analysis, more than one in eight retatrutide-treated participants were completely free of knee pain by the end of the study. Read the TRIUMPH-4 announcement.

Some of that improvement could logically result from carrying substantially less weight on damaged joints. Researchers will need to determine how much benefit comes from weight reduction versus other metabolic or inflammatory effects. Either way, it represents an important area of research.

Blood Sugar and Metabolic Health

The results extend into diabetes as well. In the Phase 3 TRANSCEND-T2D-1 study, retatrutide produced A1C reductions of as much as 2.0 percentage points while participants lost as much as 16.8% of their body weight over 40 weeks. Up to 46% of participants achieved a normal A1C. See the TRANSCEND-T2D-1 announcement.

More recent Phase 3 results announced in July 2026 found that people with obesity or overweight and type 2 diabetes lost as much as 20.8% of their body weight over 80 weeks, alongside significant improvements in glycemic control. Read Lilly’s July 2026 update.

Cardiovascular Risk, Sleep Apnea, and Beyond

The research program is becoming increasingly broad. Retatrutide studies have reported improvements in markers associated with cardiovascular risk, including triglycerides and non-HDL cholesterol. In TRIUMPH-4, the highest dose also reduced systolic blood pressure by an average of 14 mmHg under the study’s efficacy analysis.

Phase 3 research has also reported substantial improvement in moderate-to-severe obstructive sleep apnea, with apnea severity declining by as much as 60.6% in one analysis. Review the Phase 3 results announcement.

Additional research is examining retatrutide in cardiovascular and kidney outcomes, chronic kidney disease, chronic low-back pain, and metabolic dysfunction-associated steatotic liver disease (MASLD). Read Lilly’s retatrutide research overview.

The Important Caveat: Retatrutide Is Still Investigational

The excitement surrounding these results needs to be balanced with an important fact: retatrutide remains investigational. As of August 2026, it has not been approved by the FDA or another regulatory agency for public use. Lilly says it intends to submit its application to the FDA in the first quarter of 2027.

Side effects matter as well. In the published Phase 2 trial, gastrointestinal effects were the most common adverse events and were generally dose-dependent. Researchers also observed dose-dependent increases in heart rate that peaked during treatment and subsequently declined. Review the Phase 2 safety findings.

The Phase 3 program is designed to provide a much larger body of evidence about efficacy, tolerability, and safety.

A Bigger Shift in Peptide Science

Retatrutide represents something larger than a single investigational drug. We are moving from medications designed around one metabolic pathway toward molecules engineered to influence several biological signaling systems simultaneously.

GLP-1 was the beginning. Then came dual agonists. Now researchers are studying triple agonists and other multi-receptor approaches. The implications could extend well beyond obesity to diabetes, cardiovascular disease, fatty liver disease, sleep apnea, kidney disease, and other conditions connected to metabolic dysfunction.

The science is moving incredibly fast. Browse the Peptides Costa Rica blog for more research on the science, or visit the Peptides Costa Rica FAQ for general site information.

Follow the Research, Not the Hype

If you want to keep up with new peptide research, clinical trials, and the science behind emerging compounds, click this link to subscribe to the Peptides Costa Rica newsletter. We’ll continue following the research, not the hype, and breaking down what the newest studies actually tell us.

Educational content only. Nothing in this article constitutes medical advice or a recommendation to use an investigational or unapproved drug. Peptides Costa Rica products are intended strictly for laboratory research use only.